Ftse Mib
38.829,95
0,45%
DAX
23.011,75
0,32%
S&P 500
5.638,94
2,13%
NASDAQ
17.754,09
2,61%
Bitcoin
83.371,63
0,99%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ argenx SE (ARGX) argenx SE (ARGX) Notizie

argenx SE

ARGX
604,96
0,00 (0,00%)
Pre Mercato
Ultimo aggiornamento: 11:04:22
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
07/3/202512:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/3/202507:00GLOBEargenx Highlights FcRn Leadership with Long-term Data and..
27/2/202512:34EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202507:00GLOBEargenx Reports Full Year 2024 Financial Results and Provides..
25/2/202507:00GLOBEargenx to Present at TD Cowen 45th Annual Healthcare..
20/2/202507:00GLOBEargenx to Report Full Year 2024 Financial Results and Fourth..
12/2/202515:16EDGAR2Form SCHEDULE 13G/A - Statement of Beneficial Ownership by..
13/1/202507:00GLOBEargenx Highlights 2025 Strategic Priorities
06/1/202507:00GLOBEargenx to Present at 43rd Annual J.P. Morgan Healthcare..
27/12/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/12/202407:00GLOBEargenx Announces Approval of VYVDURA (efgartigimod alfa and..
26/11/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
20/11/202412:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod SC in..
12/11/202412:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/11/202413:30BWZai Lab and argenx Announce Approval of VYVGART Hytrulo for..
05/11/202407:00GLOBEargenx to Participate at Upcoming Investor Conferences
31/10/202413:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202407:00GLOBEargenx Reports Third Quarter 2024 Financial Results and..
24/10/202407:00GLOBEargenx to Report Third Quarter 2024 Financial Results and..
15/10/202414:14EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/10/202407:00GLOBEargenx Highlights Data Showing Patient Impact Across..
19/9/202412:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/9/202407:00GLOBEargenx Announces Publication in The Lancet Neurology of..
28/8/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
25/7/202412:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
25/7/202407:00GLOBEargenx Reports Half Year 2024 Financial Results and Provides..
18/7/202407:00GLOBEargenx to Report Half Year 2024 Financial Results and Second..
16/7/202423:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/7/202422:03EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/7/202406:30GLOBEargenx and Zai Lab Announce Approval of Efgartigimod Alfa..
16/7/202406:15BWZai Lab and argenx Announce Approval of Efgartigimod Alfa..
25/6/202422:30GLOBEargenx Highlights Breadth of Autoimmune Pipeline with New..
21/6/202422:50GLOBEargenx Announces FDA Approval of VYVGART Hytrulo for Chronic..
17/6/202412:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/6/202407:00GLOBEargenx to unveil its ‘Vision 2030: Taking Breakthrough..
04/6/202407:00GLOBEargenx to Present at Goldman Sachs 45th Annual Global..
09/5/202413:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/5/202407:00GLOBEargenx Reports First Quarter 2024 Financial Results and..
08/5/202412:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/5/202423:30GLOBEargenx announces results of Annual General Meeting of..
07/5/202407:00GLOBEargenx to Present at BofA Securities 2024 Health Care..
02/5/202407:00GLOBEargenx to Report First Quarter 2024 Financial Results and..
16/4/202407:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
27/3/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
Apertura: Min: Max:
Chiusura: 604,96

La tua Cronologia

NASDAQ
ARGX
argenx
NASDAQ
ARRY
Array Technologies
COIN
APTUSD
Aptos
NYSE
AVY
Avery Dennison
LSE
0HJF
Autodesk
BOV
KNOX11
FIP IE Knox CI
EU
MGT
Amundi DJ Global Titans ...
NASDAQ
FEOEX
Bmo Tactical Dividend Et...
NASDAQ
FDLPX
Bmo Global Dividend Oppo...
AQSE
HOGS.GB
WisdomTree Commodity Sec...
NASDAQ
SLDPW
Solid Power
NASDAQ
FDQBX
Bmo Global Small Cap Fun...
TG
A2RTBT
Cloverie
EU
JPN
Amundi Japan TOPIX II UC...
TG
A3KLCV
2
NYSE
EVTC
Evertec
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci